Biogen says DZP plus SoC meets primary endpoint of BICLA response at week 48
BIIB•Biogen said DZP plus standard of care met the primary endpoint of BICLA response at week 48; SRI-4 response was 60% versus 41%.
1. Trial endpoint
Biogen said DZP plus standard of care met the primary endpoint of BICLA response at week 48. SRI-4 response was 60% versus 41%.
